Spyre Therapeutics, Inc. Common Stock (SYRE) Stock Price, Quote & AI Analysis
Live SYRE stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Spyre Therapeutics, Inc. Common Stock.
TradeVae provides AI-driven analysis and real-time market intelligence for Spyre Therapeutics, Inc. Common Stock (SYRE), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Spyre Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Spyre Therapeutics, Inc. Common Stock Overview
Company information
Company Overview
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Company Details
Technical Indicators
Key technical analysis metrics and indicators
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Spyre Therapeutics, Inc. Common Stock Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...